Improving CAR T cell therapy for blood cancers by enhancing cell signaling

Increasing the efficacy of non-activated CAR T cells by modulating IFN1 signaling

NIH-funded research University of Pennsylvania · NIH-10943418

This study is looking at a new way to make CAR T cell therapy better for people with blood cancers by using special T cells that can last longer and work more effectively, which could help patients have a stronger and longer-lasting response to treatment.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Pennsylvania NIH-funded
Lab location1 site (Philadelphia, United States)
Project IDNIH-10943418 on NIH RePORTER

What this research studies

This research focuses on enhancing the effectiveness of CAR T cell therapy, which is used to treat blood cancers. The approach involves using non-activated T cells, which have better characteristics for long-term cancer control compared to activated T cells. The study aims to improve the efficiency of these non-activated T cells by using a specific protein that enhances their ability to be modified and function effectively after infusion. Patients may benefit from a more durable response to treatment as a result of this innovative method.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with blood cancers who are considering CAR T cell therapy.

Not a fit: Patients with solid tumors or those who do not have blood cancers may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective and long-lasting CAR T cell therapies for patients with blood cancers.

How similar studies have performed: Previous research has shown promising results with similar approaches to enhancing CAR T cell therapy, indicating potential for success in this study.

Where this research is happening

Philadelphia, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusCancer Model
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.